Pyxis Oncology Launches Stock Offering for Phase 3 Cancer Trial
Pyxis Oncology (PYXS) has initiated a registered public offering of common stock and warrants to raise capital. The funds will be used primarily to advance its lead cancer program, MICVO, including the planned Phase 3 trial. The announcement comes as Pyxis seeks additional resources for late-stage clinical development in oncology. However, investors reacted negatively, with PYXS shares declining following the news. This move reflects ongoing efforts by biotech firms to secure funding amid high costs of drug development and regulatory hurdles.
Tickers: $PYXS
Topics: Biotech Cancer Research Funding